Ribi ImmunoChem
Executive Summary
Results from Phase III trial comparing the biotech firm's Melacine therapeutic vaccine in advanced malignant melanoma to standard chemotherapy "showed no significant statistical advantage of one form of therapy over the other," Ribi says. Interim results from an NCI/SWOG study of Melacine in the prevention of melanoma recurrence will be available by late 1995 at the earliest